| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | Epitopes related to coeliac disease | EP10171494.7 | 2005-04-28 | EP2412380A1 | 2012-02-01 | Anderson, Robert; Beissbath, Tim; Tye-Din, Jason |
The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.
|
||||||
| 62 | ABDOMINAL CIRCULATORY PUMP DEVICE | EP10712969.4 | 2010-03-23 | EP2411093A1 | 2012-02-01 | ALIVERTI, Andrea; PEDOTTI, Antonio; MACKLEM, Peter, Tiffany; LOOMAS, Bryan, Eugene |
| The abdominal circulatory pump uses expulsive manoeuvres performed by contraction of the diaphragm while stabilizing, contracting or compressing the abdominal wall to increase abdominal pressure and pump blood. At the same time, it can be used to lower pleural pressure around the surface of the lung to provide ventilation. In humans the blood in the splanchnic circulation; i.e., the blood in the abdominal contents, is a reservoir of about 20% to 25% of the whole body blood volume. The increase in abdominal pressure forces this blood to flow out of the abdomen and through the body. | ||||||
| 63 | 用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物 | TW106119998 | 2017-06-15 | TW201803591A | 2018-02-01 | 里昂 法蘭西斯可; LEON, FRANCISCO; 朱靜 韋恩H; TSUJI, WAYNE H. |
| 本文提供用於治療炎性病症，具體而言，乳糜瀉、難治性乳糜瀉、及非乳糜瀉麩質敏感的方法及醫藥組成物。 | ||||||
| 64 | 乳糜瀉和食物過敏之膳食管理 | TW102119600 | 2013-06-03 | TW201410251A | 2014-03-16 | 譚波良 格雷琴; TANBONLIONG, GRETCHEN |
| 本發明透過經腸投予有效量之至少一種水解蛋白及雷曼氏乳酸桿菌GG(LGG)提供膳食管理個體(如哺餵配方奶之嬰幼兒)之乳糜瀉及食物過敏的組成物及方法。本發明之營養組成物可包含除了有效量之LGG的益生菌成分以外，水解蛋白成分、脂質成分、碳水化合物成分、維生素成分、礦物質成分及益菌生成分。 | ||||||
| 65 | DIAGNOSTIC METHOD FOR CELIAC SPRUE | EP03789958.0 | 2003-11-20 | EP1563300B1 | 2012-04-18 | KHOSLA, Chaitan; SHAN, Lu |
| Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. | ||||||
| 66 | Diagnosis of coeliac disease using a gliadin epitope | PCT/GB0003760 | 2000-10-02 | WO0125793A3 | 2001-08-23 | ANDERSON ROBERT PAUL; HILL ADRIAN VIVIAN SINTON; JEWELL DEREK PARRY |
| A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: (a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is: SEQ ID NO: 1 or 2, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID N0:3, (ii) an epitope comprising sequence comprising: SEQ ID NO:1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO:3, which epitope is an isolated oligopeptide derived from a gliadin protein, (iii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining in vitro whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease. Therapeutic compositions which comprise the epitope and gliadin proteins which do not cause coeliac disease are also provided. | ||||||
| 67 | TREATMENT OF CELIAC DISEASE | EP99917810.6 | 1999-05-06 | EP1075267A2 | 2001-02-14 | SJÖSTRÖM, Hans; NOR N, Ove |
| The present invention relates to a method of treating celiac disease comprising interfering with the deamidation of at least one glutamine residue in a gliadin or glutenin molecule. This may be provided by prohibiting or interfering with the deamidation of at least one glutamine residue by derivation of at least one glutamine residue in a gliadin or glutenine molecule in wheat flour by a chemical or enzymatic deamidation of gluten followed by chemical or enzymatic derivation of the generated carboxyl group(s). In a further aspect, the invention relates to a method of interfering with the deamidation of at least one glutamine residue in a gliadin or glutenin molecule and thereby treating celiac disease, the method comprising administering, to a patient having or suspected of having celiac disease, at least one of the following substances: (a) a substance which is capable of increasing the pH in the gastroduodenal tract of a subject, e.g. an antacidum, an anticholinergic agent, H2-receptor antagonists or a proton pump inhibitor, (b) a substance which is capable of eliminating deamidating bacteria in the gastroduodenal tract of a subject, e.g. an antibiotic or antimicrobial agent, and/or (c) a substance which is capable of interfering with the effect of at least one deamidating enzyme in the gastroduodenal tract of a subject. | ||||||
| 68 | Method for treating celiac disease | US13449819 | 2012-04-18 | US09241969B2 | 2016-01-26 | Blake Paterson; Mark J. Ginski |
| Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine. | ||||||
| 69 | Agents for the treatment of celiac disease | US13131787 | 2009-11-30 | US08835603B2 | 2014-09-16 | Robert P. Anderson; Jessica A. Stewart; James A. Dromey; Jason A. Tye-Din |
| The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients. | ||||||
| 70 | Method for treating celiac disease | US12616638 | 2009-11-11 | US08168594B2 | 2012-05-01 | Blake Paterson; Mark J. Ginski |
| Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine. | ||||||
| 71 | 乳糜瀉和食物過敏之膳食管理 | TW102119600 | 2013-06-03 | TWI639438B | 2018-11-01 | 譚波良 格雷琴; TANBONLIONG, GRETCHEN |
| 本發明透過經腸投予有效量之至少一種水解蛋白及雷曼氏乳酸桿菌GG(LGG)提供膳食管理個體(如哺餵配方奶之嬰幼兒)之乳糜瀉及食物過敏的組成物及方法。本發明之營養組成物可包含除了有效量之LGG的益生菌成分以外，水解蛋白成分、脂質成分、碳水化合物成分、維生素成分、礦物質成分及益菌生成分。 | ||||||
| 72 | Epitopes related to coeliac disease | US13541864 | 2012-07-05 | US09017690B2 | 2015-04-28 | Robert Anderson; Tim Beissbath; Jason Tye-Din |
| The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided. | ||||||
| 73 | Lactic Acid Bacteria for Coeliac Disease | US13634458 | 2010-03-12 | US20130121976A1 | 2013-05-16 | Agusti Montserrat Carreras; Montserrat Andreu Corominas; Daniel Ramon Vidal; Salvador Genoves Martinez; Esther Bataller Leiva |
| The present invention discloses strains of Lactobacillus and Streptococcus which have a capacity to degrade gliadin peptides involved in coeliac disease and which peptide degrading activity is stable under low pH and in the presence of mammalian digestive enzymes. These strains are suitable in a product for use in prevention and/or treatment of celiac disease. | ||||||
| 74 | Method for treating celiac disease | US09626151 | 2000-07-26 | US06348495B1 | 2002-02-19 | Claudio Cavazza; Luigi Mosconi |
| A method for treating celiac disease comprising administration of a composition containing an alkanoyl L-carnitine wherein the alkanoyl group is straight or branched and has 2-6 carbon atoms and the pharmacologically acceptable salts thereof. | ||||||
| 75 | DIAGNOSTIC METHOD FOR CELIAC SPRUE | EP03789958.0 | 2003-11-20 | EP1563300A2 | 2005-08-17 | KHOSLA, Chaitan; SHAN, Lu |
| Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. | ||||||
| 76 | 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템 | KR1020177011301 | 2015-10-08 | KR1020170067795A | 2017-06-16 | 피멘텔,마크; 창,크리스토퍼 |
| 과민성장 증후군 (IBS)을, 염증성장 질환 (IBD) 및셀리악병과구별하기위한방법및 시스템이본원에기술된다. 상기방법은 IBS를 IBD 및셀리악병과구별하기위한항-빈쿨린항체및 항-CdtB 항체의검출을이용할수 있다. IBS, IBD 또는셀리악병을치료하기위한요법을선택하기위한방법이추가로기술된다. | ||||||
| 77 | 선인장 진액의 추출방법 및 선인장 진액을 추출하여 미용비누를 제조하는 방법 | KR1020030019547 | 2003-03-28 | KR100526759B1 | 2005-11-08 | 김수남 |
| 본 발명은 물과 폴리에틸렌글리콜(Polyethylene Glycol)을 이용해 손바닥 선인장의 진액(엑기스, 유효성분)을 추출하는 방법 및 선인장 진액을 추출하여 미용비누를 제조하는 방법에 관한 것으로, 선인장 과육을 착즙한 것과는 달리 추출된 선인장 진액(엑기스)은 안정성이 뛰어나 오랜 기간 보관해도 부패되지 않으며, 이를 이용하여 제조된 미용비누는 쉽게 물러지거나 균열이 생기지 않을 뿐만 아니라 피부 자극이 적고, 소염 작용과 보습력이 우수한 특징이 있다. | ||||||
| 78 | 신규한 락토코커스 가르비에 박테리오파지 Ｌａｃ-ＧＡＰ-1 및 이의 락토코커스 가르비에 균 증식 억제 용도 | KR1020150008012 | 2015-01-16 | KR1020160088650A | 2016-07-26 | 윤성준; 강상현; 전수연; 권안성; 황순혜 |
| 본발명은락토코커스가르비에균을특이적으로사멸시킬수 있는능력을갖는서열번호 1로표시되는유전체를갖는것을특징으로하는자연으로부터분리한미오비리대박테리오파지 Lac-GAP-1(수탁번호 KCTC 12686BP), 및이를유효성분으로포함하는조성물을이용한락토코커스가르비에균의감염을방지및 처치하는방법에관한것이다. | ||||||
| 79 | 신규한 클로스트리디움 퍼프린젠스 박테리오파지 Ｃｌｏ-ＰＥＰ-1 및 이의 클로스트리디움 퍼프린젠스 증식 억제 용도 | KR1020140191675 | 2014-12-29 | KR1020160080175A | 2016-07-07 | 윤성준; 강상현; 전수연; 손지수; 백형록; 박석황 |
| 본발명은클로스트리디움퍼프린젠스균을특이적으로사멸시킬수 있는능력을갖는서열번호 1로표시되는유전체를갖는것을특징으로하는미오비리대박테리오파지 Clo-PEP-1 (수탁번호 KCTC 12664BP), 및이를유효성분으로포함하는조성물을이용한클로스트리디움퍼프린젠스균의감염을방지및 처치하는방법에관한것이다. | ||||||
| 80 | PROCESS TO INFECT CRUSTACEANS WITH INFECTIOUS AGENTS | EP16712303.3 | 2016-03-22 | EP3273775A1 | 2018-01-31 | NAUWYNCK, Hans |
| The present invention relates to the field of aquaculture of commercially important crustaceans such as penaeid shrimp. The present invention discloses a process to effectively infect crustaceans via inoculating pathogens directly into the external pore of the antennal gland of said crustaceans. This new portal of entry for pathogens can be used to investigate and/or prevent infection of crustaceans with pathogens such as white spot syndrome virus. | ||||||
QQ群二维码
意见反馈
意见反馈